Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimized Dual Therapy vs Bismuth Quadruple Therapy for First-line H. pylori Eradication
ChiCTR-IPR-17010774Phase 4Recruiting
- Sponsor
- Army Specialized Medical Center
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of omeprazole, amoxicillin, bismuth subsalicylate, clarithromycin and metronidazole in Helicobacter pylori infection, chronic gastritis and Peptic ulcer disease (PUD) (2 arms), sponsored by Army Specialized Medical Center. Primary endpoint: Helicobacter pylori eradication rate. Started Feb 2017; status: recruiting.
02
Drugs
omeprazoleamoxicillinbismuth subsalicylateclarithromycinmetronidazole
03
Conditions
Helicobacter pylori infectionchronic gastritisPeptic ulcer disease (PUD)
Beyond the preview
Go deeper on ChiCTR-IPR-17010774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17010774.